OPFOLDA

搜索文档
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
Seeking Alpha· 2025-08-02 04:04
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...
Amicus Therapeutics(FOLD) - 2025 Q2 - Earnings Call Transcript
2025-07-31 21:30
Amicus Therapeutics (FOLD) Q2 2025 Earnings Call July 31, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics Second Quarter twenty twenty five Financial Results Conference Call and Webcast. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Mr.An ...